Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

October 9, 2015

Primary Completion Date

September 12, 2019

Study Completion Date

November 28, 2019

Conditions
Crohn's Disease
Interventions
DRUG

RPC1063

Trial Locations (28)

1030

Kyiv CCH #18 Dept of Proctology O. O. Bogomolets NMU, Kyiv

7100

Tolna Megyei Balassa Janos Korhaz, Szekszárd

20815

Chevy Chase Clinical Research, Chevy Chase

21018

Vinnytsia Regional Clinical, Vinnytsia

29118

Gastroenterology Associates of Orangeburg, Orangeburg

30024

Atlanta Gastroenterology Specialists PC, Suwanee

33157

IMIC, Inc., Palmetto Bay

33777

Florida Center for Gastroenterology, Largo

38138

Gastro One, Germantown

43210

Ohio State University Clinical Trials Management Office, Columbus

45267

UC Health Clinical Trials Office, Cincinnati

49074

Si Institute Of Gastroenterology Of Namsu Dept Of Stomach And Duodenum Diseases, Dnipropetrovsk

61037

Kharkiv City Clinical Hospital 2, Kharkiv

64012

Ehrhardt Clinical Research LLC, Belton

69104

CI City Hospital #1, Zaporizhia

70809

Gastroenterology Associates LLC, Baton Rouge

78229

San Antonio Gastroenterology, San Antonio

79010

Lviv Regional Clinical Hospital, Lviv

85712

Adobe Clinical Research LLC, Tucson

60453-3767

DM Clinical Research, Oak Lawn

N6A 5W9

LHSC Victoria Hospital, London

H-1032

Szent Margit Korhaz, Budapest

90-302

Santa Familia Centrum Badan, Profilaktyki i Leczenia, Lodz

20-582

GASTROMED Sp.zo.o., Lublin

00-632

Centrum Zdrowia Matki, Dziecka i Mlodziezy, Warsaw

02-507

Centralny Szpital Kliniczny MSWIA, Warsaw

03-580

Nzoz Vivamed, Warsaw

04107

Municipal Institution of Kyiv Regional Council Kyiv Regional Clinical Hospital, Kyiv

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celgene

INDUSTRY